Maravai LifeSciences vs Schrodinger
MRVI and SDGR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MRVI and SDGR compare
Schrodinger is the larger company, worth 1.2 times as much as Maravai LifeSciences ($2.4B against $2.0B).
Maravai LifeSciences grew revenue faster over the last twelve months (10.7% versus 4.8% for Schrodinger).
Schrodinger keeps more of each dollar of sales as profit, with a net margin of −22.0% compared with −30.8% at Maravai LifeSciences.
Schrodinger scores higher on the StockData Score (12 against 8 for Maravai LifeSciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MRVI | SDGR |
|---|---|---|
| Size and price | ||
| Market cap | $2.0B | $2.4B |
| Share price | $7.70 | $31.52 |
| Change, 1 year | 148% | 72.3% |
| Change, 5 years | −79.4% | −22.7% |
| Beta (5Y) | 1.02 | 1.85 |
| Employees | 435 | 850 |
| StockData Score | ||
| Total score | 8 | 12 (better) |
| Valuation score | 0 | 0 |
| Growth score | 3 | 3 |
| Performance score | 2 | 3 (better) |
| Health score | 3 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 9.4× | 8.8× (better) |
| P/B | 10.2× | 7.8× (better) |
| FCF yield | −0.66% (better) | −5.0% |
| Fair value | $2.66 | $17.66 |
| Margin of safety | −190% | −78.5% (better) |
| Growth | ||
| Revenue growth (TTM) | 10.7% (better) | 4.8% |
| Revenue growth, 5Y average | −8.1% | 18.8% (better) |
| Profitability | ||
| Gross margin | 39.1% | 58.5% (better) |
| Operating margin | −45.4% (better) | −49.6% |
| Net margin | −30.8% | −22.0% (better) |
| FCF margin | −6.2% (better) | −43.4% |
| Return on equity | −29.8% | −19.0% (better) |
| Return on invested capital | −27.0% | – |
| Financial health | ||
| Debt / equity | 0.75 (better) | 0.00 |
| Interest coverage | −4.6× | – |
| Current ratio | 4.66 (better) | 2.75 |
| Altman Z-score | 4.63 (better) | 3.20 |
| Piotroski F-score | 2 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 55.5% | 86.5% |
| Held by insiders | 54.1% | 3.2% |
| Insider net buying, 12 months | $115K (better) | −$3.4M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 11.8% | 13.5% |
Go deeper
- MRVI stock overview
- MRVI income statement
- MRVI valuation and score
- SDGR stock overview
- SDGR income statement
- SDGR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.